Latest News by Industry
![Voyager Therapeutics, Inc. [VYGR] reports annual net loss of $132.3 million](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FVYGR.png&w=1200&q=75)
Voyager Therapeutics, Inc. [VYGR] has reported a net loss of $132.3 million for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $250.0 million
Based in LEXINGTON, Massachusetts, Voyager Therapeutics, Inc. operates in the MANUFACTURING sector.
In the Consolidated Statements of Operations and Comprehensive Income (Loss) for the period ending December 31, 2023, the company reported collaboration revenue of $250.008 million, a significant increase compared to $40.907 million in the same period in 2022 and $37.415 million in 2021.
Operating expenses for the current period included research and development costs of $92.172 million, higher than the $60.764 million in 2022 and $73.787 million in 2021. General and administrative expenses were $35.822 million, up from $30.980 million last year and $37.246 million in 2021. The total operating expenses for this period amounted to $127.994 million, compared to $91.744 million in 2022 and $111.033 million in 2021.
The company reported an operating income of $122.014 million for the current period, a significant improvement from the operating loss of $50.837 million in 2022 and $73.618 million in 2021.
Other income, net, including interest income and other sources, totaled $11.724 million for the current period, compared to $4.445 million in 2022 and $2.421 million in 2021.
The income before income taxes for the period was $133.738 million, marking a substantial increase from the loss of $46.392 million in 2022 and $71.197 million in 2021. The income tax provision for the current period was $1.408 million.
The net income for the period was $132.330 million, a significant improvement from the net loss of $46.408 million in 2022 and $71.197 million in 2021. The comprehensive income for the current period was $132.501 million.
Regarding earnings per share, the company reported a basic net income per share of $3.08, an improvement from the previous year's loss per share of $1.21 and $1.89 in 2021. The diluted net income per share was $2.97, compared to the loss per share of $1.21 in 2022 and 2021.
Weighted-average common shares outstanding increased to 43,020,747 in the current period, up from 38,356,810 in 2022 and 37,668,947 in 2021. The weighted-average common shares outstanding for diluted earnings per share were 44,569,334 in the current period.
In conclusion, the company has shown significant improvement in key financial metrics compared to the previous periods, reflecting a positive trend in its financial performance.
Also Read: